Stay up-to-date on new clinical findings in Oncoderm.

Oncoderm Articles

Oncoderm Articles

Grover Disease Associated With Chemotherapy: Review of Potential Pathophysiology, Current Treatments, and Future Directions

History of Transient Acantholytic Dermatosis (Grover Disease)
Transient acantholytic dermatosis, or Grover disease, is a rare acantholytic skin disorder that was first described by Dr. Ralph Weir Grover.1 Over the course of five years, he observed six patients who presented with unusual transient truncal rashes. In 1970, he published a case series of these six patients and observed that the histology indicated an acantholytic process that seemed consistent with Hailey-Hailey disease or Darier disease.

Transient Acantholytic Dermatosis (Grover Disease) Associated With Chemotherapy: Review of Potential Pathophysiology, Current Treatments and Future Directions for Treatment

Transient acantholytic dermatosis has been frequently reported in patients with malignancies. While paraneoplastic cases have been reported, most eruptions occur in the setting of chemotherapeutic agents. Management is based on limited data and primarily with topical steroids and topical emollients. A subset of patients exhibits recalcitrant disease and require alternate therapeutic approaches.

The Influence of Supportive Oncodermatology Interventions on Patient Quality of Life: A Cross-Sectional Survey

Supportive oncodermatology is a growing field that provides treatment and preventive care to oncology patients who experience dermatologic adverse events (dAEs) secondary to cytotoxic and targeted cancer treatments. Novel cancer therapies that impede the proliferation of cancer cells often target other rapidly proliferating organ systems and can lead to unfavorable skin, hair, and nail alterations.

Read More Articles

Oncoderm Editorials

Radiation Dermatitis: Current Perspectives and Future Directions

Radiation therapy is a commonly used and clinically important treatment for a variety of malignancies. The limiting factor in radiation treatment is often skin tolerance, as radiation injury to healthy skin is a frequent complication.1 Although it is not the primary therapeutic target, the skin undergoes molecular, gross, and functional changes as a result of radiation therapy,2-4resulting in adverse events.

Resident Rounds. Program Spotlight: Weill Cornell Medical College

This issue of Resident Rounds features Weill Cornell Medical College. The editor of Resident Rounds is Omar A. Ibrahimi MD PhD. He is currently the Founding and Medical Director of the Connecticut Skin Institute. Dr. Ibrahimi is also a Visiting Assistant Professor of Dermatology Wellman Center for Photomedicine at Massachusetts General Hospital/Harvard Medical School. If you are interested in highlighting your training program in a future issue, please contact Dr. Ibrahimi at

Read More Editorials



Saving Skin, Hair & Nails with Supportive Oncodermatology: A Call to Action for All Those Involved

While the old adage, “more oncology treatments, more skin problems,” becomes more like dogma every day with each new life saving therapy, fear not my friends, help is out there. Joining JDD podcast host Dr. Adam Friedman again, the man, the myth, the supportive oncodermatology legend, Dr. Mario Lacouture shares the latest guidance on managing these hair, skin and nail toxicities that are often considered by the patient even worse then the cancer these drugs treat. Get your support on – your patients will thank you.
This podcast series is supported by La Roche-Posay.


Listen Now

Heal the Burn: Radical Updates for the Management of Radiation Dermatitis

All of those wonderful life saving toys the radiation oncologists get to play with come at a cost to an important bystander – the skin. Radiation dermatitis can be exquisitely disabling, and interfere with a patient’s treatment course. Enter Dr. Beth McLellan, Chief of Dermatology at the Albert Einstein College of Medicine who is soothing XRT burns and taking names. Tune in to part two of this three part supportive oncodermatology series as host Dr. Adam Friedman discusses how to best coordinate care with our oncology friends and manage and hopefully prevent this expected adverse event with this one rad derm. Phasers set to educate.
This podcast series is supported by La Roche-Posay.


Listen Now


US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm

An increasing number of patients survive or are living with cancer. Anticancer treatments frequently have cutaneous adverse events (cAEs) that may severely impact patients’ quality of life and interrupt anticancer treatment. The US Cutaneous Oncodermatology Management (USCOM) project aims to improve cancer patients’ and survivors’ quality of life by offering tools for preventing and managing cAEs.

Read More